Brevan Howard Capital Management’s Vir Biotechnology VIR Stock Holding History

Brevan Howard Capital Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Buy	+21,598	New	+$205K	﹤0.01%	1861
2026 Q1	–	Sell	-49,623	Closed	-$299K	–	2518
2025 Q4	$299K	Buy	+49,623	New	+$295K	﹤0.01%	1373
2025 Q3	–	Sell	-34,743	Closed	-$175K	–	2308
2025 Q2	$175K	Sell	34,743 -69,579	-67%	-$373K	﹤0.01%	1734
2025 Q1	$676K	Buy	104,322 +83,689	+406%	+$744K	0.01%	629
2024 Q4	$151K	Buy	+20,633	New	+$163K	﹤0.01%	939
2024 Q3	–	Sell	-46,087	Closed	-$410K	–	1460
2024 Q2	$410K	Buy	+46,087	New	+$442K	﹤0.01%	675

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Brevan Howard Capital Management's VIR Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Vir Biotechnology (VIR) in Q2 2026: 21,598 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #1861 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in VIR as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in VIR in Q2 2024 and has held it in 6 quarters since. The position peaked at $676K in Q1 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Brevan Howard Capital Management held 21,598 shares of Vir Biotechnology worth $220K as of Q2 2026.
Vir Biotechnology was a new Brevan Howard Capital Management position in Q2 2026.
Vir Biotechnology made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1861 holding.
Brevan Howard Capital Management first reported a position in Vir Biotechnology in Q2 2024 and has held it in 6 quarters since.
Brevan Howard Capital Management's Vir Biotechnology position peaked at $676K in Q1 2025.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.